A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and the EGFR pathway. Both resistance mechanisms can occur at the same time, in the same patient and even in the same tumor. This study combines a second generation EGFR inhibitor and a cMET inhibitor to block both these pathways in order to overcome resistance and treat this disease.
Checked against the public recordLast updated Oct 28, 2015 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Pfizer
- Interventions being studied
- Drug: PF-02341066; Drug: PF-00299804; Drug: PF-02341066; Drug: PF-00299804
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * advanced non small cell lung cancer (dose escalation phase) * acquired resistance to erlotinib or gefitinib (expansion phase) * mandatory entrance biopsy (expansion phase) Exclusion Criteria: * interstitial lung disease * unstable brain metastases * leptomeningeal disease
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Clinical Trials Office University of Colorado Hospital (CTO)Aurora, Colorado
- DRUG SHIPMENT: University of Colorado Cancer CenterAurora, Colorado
- Rocky Mountain Lions Eye InstituteAurora, Colorado
- University of Colorado HospitalAurora, Colorado
- CCR, National Cancer InstituteBethesda, Maryland
- Drug Shipment OnlyBoston, Massachusetts
- Massachusetts General HospitalBoston, Massachusetts
- Brigham & Women's HospitalBoston, Massachusetts
- Drug Shipment OnlyBoston, Massachusetts
- Peter MacCallum Cancer Centre, Division of Haematology and Medical OncologyEast Melbourne, Victoria
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 28, 2015. Always confirm current availability with the study team.